References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
Generic HIV medications contain the same active ingredients as branded drugs but cost significantly less. As patents expire on older antiretrovirals, generic versions become available, making HIV treatment more affordable for healthcare systems and more accessible for patients worldwide.
In the UK, the NHS provides all HIV medication free of charge regardless of whether it’s branded or generic. However, generic availability influences which drugs are prescribed and helps reduce the overall cost of HIV treatment to the NHS.
What Is a Generic Drug?
A generic drug has the same active ingredient, dosage, strength, and route of administration as the branded original. It must meet the same quality and safety standards. The main differences are the name, packaging, and price. Regulatory agencies (MHRA in the UK, EMA in Europe) require generics to demonstrate bioequivalence before approval.
HIV Drugs Available as Generics in the UK
| Generic Name | Brand Name | Class | Generic Available? |
|---|---|---|---|
| Tenofovir disoproxil / emtricitabine | Truvada | NRTI backbone | Yes |
| Efavirenz | Sustiva | NNRTI | Yes |
| Efavirenz / emtricitabine / tenofovir | Atripla | Single-tablet regimen | Yes |
| Abacavir / lamivudine | Kivexa | NRTI backbone | Yes |
| Lopinavir / ritonavir | Kaletra | PI | Yes |
| Raltegravir | Isentress | INSTI | Yes |
| Dolutegravir | Tivicay | INSTI | Yes (some markets) |
| Darunavir | Prezista | PI | Yes |
Newer drugs like bictegravir (in Biktarvy), doravirine (Pifeltro), and cabotegravir are still under patent and not yet available as generics.
Are Generics as Effective as Branded Drugs?
Yes. Generic HIV medications must demonstrate bioequivalence, meaning they achieve the same blood levels and therapeutic effect as the branded version. Multiple studies have confirmed that switching from branded to generic HIV drugs maintains viral suppression with no increase in side effects.
The NHS routinely prescribes generic HIV medications when available. If your pharmacy gives you a different-looking tablet or box, this is likely a switch to a generic. The medication inside works the same way.
How Generics Reduce NHS Costs
HIV treatment costs the NHS approximately £300-£800 per month per patient for branded drugs. Generic equivalents can cost 50-90% less. The savings from generic prescribing are reinvested into HIV care, testing programmes, and PrEP provision.
Read more: What is HIV? | Starting HIV treatment | One-pill-a-day HIV treatments
Frequently Asked Questions
Will my doctor switch me to a generic without telling me?
Your HIV clinic should discuss any medication changes with you. In practice, pharmacy-level substitution of branded for generic can happen without a specific conversation, but the active drug remains the same. If you notice a change in your tablets, ask your pharmacist to confirm.
Can I request the branded version?
In the UK, the NHS generally prescribes the most cost-effective option. If you have a specific concern (e.g., allergy to an inactive ingredient in the generic), your doctor can request the branded version, but this is uncommon.
Are generic PrEP drugs available?
Yes. Generic tenofovir/emtricitabine (generic Truvada) is available and is what the NHS PrEP programme primarily uses. It’s equally effective as branded Truvada. Read more: What is PrEP?
Related reading
- Injectable HIV Treatment: Everything You Need to Know
- Are HIV Tests Accurate If You're on PrEP, PEP or ART?
- CD4/CD8 Ratio: What It Means and Why It Matters
- CD4 Counts Explained: What Your Numbers Mean
- Changing HIV Treatment: When, Why and How
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
